Arcus Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Arcus Biosciences, Inc. (NYSE: RCUS) on March 10, 2023, reporting events that occurred on March 9, 2023. The filing addresses changes in the Company's senior financial leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
- Appointment of Principal Accounting Officer: The Board of Directors appointed Alexander Azoy as the Company's Principal Accounting Officer.
- Role Transition: Robert C. Goeltz II, the Chief Financial Officer, ceased to function as the Principal Accounting Officer concurrent with Mr. Azoy's appointment.
- Reporting Structure: Mr. Azoy will continue to report to Mr. Goeltz.
Management Commentary and Compensation
Mr. Azoy, age 47, has served as Vice President of Finance since October 2020. He brings extensive experience from Unity Biotechnology, Sienna Biopharmaceuticals, Kythera Biopharmaceuticals, and Ernst & Young. He holds a B.S. in Accounting and is a certified public accountant in California.
Mr. Azoy has entered into the Company's standard severance and change of control agreement. Key terms include:
- Specified cash severance, medical premium payments, and accelerated vesting of equity awards upon termination under specified conditions within 12 months of a change of control.
- Participation in the severance program for terminations without cause (not in connection with a change of control), which includes cash severance, medical premiums, and a potential pro-rata bonus.
Investor Verification Checklist
- Verify the effective date of Alexander Azoy's appointment as Principal Accounting Officer.
- Confirm the continued role of Robert C. Goeltz II as Chief Financial Officer.
- Review the specific terms of the severance and change of control agreement for Mr. Azoy in the Company's proxy statements or other filings.
- Check for any subsequent filings regarding further changes to the finance leadership team.